JP5779750B2 - 血管新生療法用医薬組成物 - Google Patents

血管新生療法用医薬組成物 Download PDF

Info

Publication number
JP5779750B2
JP5779750B2 JP2011528658A JP2011528658A JP5779750B2 JP 5779750 B2 JP5779750 B2 JP 5779750B2 JP 2011528658 A JP2011528658 A JP 2011528658A JP 2011528658 A JP2011528658 A JP 2011528658A JP 5779750 B2 JP5779750 B2 JP 5779750B2
Authority
JP
Japan
Prior art keywords
hpgis
vegf
gene
aav
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011528658A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2011024480A1 (ja
Inventor
恵一 福田
恵一 福田
崇史 川上
崇史 川上
田邉　忠
忠 田邉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2011528658A priority Critical patent/JP5779750B2/ja
Publication of JPWO2011024480A1 publication Critical patent/JPWO2011024480A1/ja
Application granted granted Critical
Publication of JP5779750B2 publication Critical patent/JP5779750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
    • C12Y503/99004—Prostaglandin-I synthase (5.3.99.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011528658A 2009-08-31 2010-08-30 血管新生療法用医薬組成物 Active JP5779750B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011528658A JP5779750B2 (ja) 2009-08-31 2010-08-30 血管新生療法用医薬組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009200900 2009-08-31
JP2009200900 2009-08-31
JP2011528658A JP5779750B2 (ja) 2009-08-31 2010-08-30 血管新生療法用医薬組成物
PCT/JP2010/005321 WO2011024480A1 (ja) 2009-08-31 2010-08-30 血管新生療法用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015045546A Division JP5973605B2 (ja) 2009-08-31 2015-03-09 血管内皮増殖因子（ｖｅｇｆ）の産生誘導剤

Publications (2)

Publication Number Publication Date
JPWO2011024480A1 JPWO2011024480A1 (ja) 2013-01-24
JP5779750B2 true JP5779750B2 (ja) 2015-09-16

Family

ID=43627595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011528658A Active JP5779750B2 (ja) 2009-08-31 2010-08-30 血管新生療法用医薬組成物
JP2015045546A Active JP5973605B2 (ja) 2009-08-31 2015-03-09 血管内皮増殖因子（ｖｅｇｆ）の産生誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015045546A Active JP5973605B2 (ja) 2009-08-31 2015-03-09 血管内皮増殖因子（ｖｅｇｆ）の産生誘導剤

Country Status (5)

Country Link
US (4) US20120156170A1 (https=)
EP (1) EP2474325B1 (https=)
JP (2) JP5779750B2 (https=)
CN (1) CN102573924A (https=)
WO (1) WO2011024480A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021230361A1 (en) * 2020-03-04 2022-09-08 Poseida Therapeutics, Inc. Compositions and methods for the treatment of Metabolic Liver Disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535091T2 (de) 1994-04-28 2007-01-04 Tanabe, Tadashi, Toyonaka Humane prostacyclinsynthase
CA2230819C (en) 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
AU6893100A (en) * 1999-08-02 2001-02-19 Avigen, Inc. Use of recombinant adeno-associated virus vector (raav) for the prevention of smooth muscle cell proliferation in vascular graft
JP4632481B2 (ja) * 2000-05-22 2011-02-16 忠 田邉 プロスタサイクリン合成酵素遺伝子含有医薬組成物
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6010059811; ＫＡＷＡＫＡＭＩ，　Ｔ　ｅｔ　ａｌ: 'Ａｄｅｎｏ-ａｓｓｏｃｉａｔｅｄ　Ｖｉｒｕｓ-ｍｅｄｉａｔｅｄ　Ｐｒｏｓｔａｇｌａｎｄｉｎ　Ｉ２　Ｓｙｎｔｈａｓｅ　（ＰＧＩＳ）　Ｇｅｎｅ　Ｔｒａｎｓｆｅｒ　Ｉｍｐｒｏｖｅｓ　ａ　Ｌｉｍｂ　Ｉｓｃｈｅ' Ｃｉｒｃ　Ｊ Ｖｏｌ．７３，　Ｎｏ．Ｓｕｐｐｌｅｍｅｎｔ　１, 20090301, ｐ．５９２-５９３ *
JPN6010059815; ＫＡＷＡＫＡＭＩ，Ｔ．　ｅｔ　ａｌ: 'ＡＡＶ-ＰＧＩＳ　ｇｅｎｅ　ｔｒａｎｓｆｅｒ　ｉｍｐｒｏｖｅｓ　ｈｙｐｏｘｉａ-ｉｎｄｕｃｅｄ　ｐｕｌｍｏｎａｒｙ　ｈｙｐｅｒｔｅｎｓｉｏｎ　ｉｎ　ｍｉｃｅ' Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　ｂｉｏｐｈｙｓｉｃａｌ　ｒｅｓｅａｒｃｈ　ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．３６３，　Ｎｏ．３, 2007, ｐ．６５６-６１ *
JPN6010059818; ＹＡＮ，Ｈ．　ｅｔ　ａｌ: 'Ｓｕｐｅｒｉｏｒ　ｎｅｏｖａｓｃｕｌａｒｉｚａｔｉｏｎ　ａｎｄ　ｍｕｓｃｌｅ　ｒｅｇｅｎｅｒａｔｉｏｎ　ｉｎ　ｉｓｃｈｅｍｉｃ　ｓｋｅｌｅｔａｌ　ｍｕｓｃｌｅｓ　ｆｏｌｌｏｗｉｎｇ　ＶＥＧＦ　ｇｅｎｅ' Ｂｉｏｃｈｅｍ　Ｂｉｏｐｈｙｓ　Ｒｅｓ　Ｃｏｍｍｕｎ Ｖｏｌ．３３６，　Ｎｏ．１, 2005, ｐ．２８７-９８ *
JPN7010003302; ＨＩＲＡＯＫＡ，Ｋ．　ｅｔ　ａｌ: 'Ｅｎｈａｎｃｅｄ　ｔｈｅｒａｐｅｕｔｉｃ　ａｎｇｉｏｇｅｎｅｓｉｓ　ｂｙ　ｃｏｔｒａｎｓｆｅｃｔｉｏｎ　ｏｆ　ｐｒｏｓｔａｃｙｃｌｉｎ　ｓｙｎｔｈａｓｅ　ｇｅｎｅ　ｏｒ　ｏｐｔｉｍｉｚａｔｉｏｎ　ｏｆ' Ｃｉｒｃｕｌａｔｉｏｎ Ｖｏｌ．１０８，　Ｎｏ．２１, 2003, ｐ．２６８９-９６ *
JPN7010003303; ＨＡＵＣＫ，Ｂ．　ｅｔ　ａｌ: 'Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ｔｉｓｓｕｅ　ｔｒｏｐｉｓｍ　ｄｅｔｅｒｍｉｎａｎｔｓ　ｏｆ　ａｄｅｎｏ-ａｓｓｏｃｉａｔｅｄ　ｖｉｒｕｓ　ｔｙｐｅ　１' Ｊ　Ｖｉｒｏｌ Ｖｏｌ．７７，　Ｎｏ．４, 2003, ｐ．２７６８-７４ *

Also Published As

Publication number Publication date
JP5973605B2 (ja) 2016-08-23
US20190224257A1 (en) 2019-07-25
EP2474325A4 (en) 2013-01-16
US20170119829A1 (en) 2017-05-04
CN102573924A (zh) 2012-07-11
EP2474325B1 (en) 2017-06-21
US20120156170A1 (en) 2012-06-21
US11666615B2 (en) 2023-06-06
US11298386B2 (en) 2022-04-12
US20200171109A1 (en) 2020-06-04
WO2011024480A1 (ja) 2011-03-03
EP2474325A1 (en) 2012-07-11
JPWO2011024480A1 (ja) 2013-01-24
JP2015108024A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
JP3961019B2 (ja) 遺伝子転移媒介の血管形成療法
US7994151B2 (en) Compositions and methods for angiogenic therapy utilizing genes encoding ets-1
KR20000070572A (ko) 혈관형성 유도용 아데노바이러스 벡터의 다중 부위 운반
EA005157B1 (ru) Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
JP2003513932A (ja) 血管形成の誘導方法
US20170252462A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
JP5973605B2 (ja) 血管内皮増殖因子（ｖｅｇｆ）の産生誘導剤
JP5300157B2 (ja) 血管新生療法用医薬組成物
HK1008979B (en) Gene transfer-mediated angiogenesis therapy
HK1055247A (en) Medicinal compositions for angiogenic therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150519

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150522

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150629

R150 Certificate of patent or registration of utility model

Ref document number: 5779750

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250